In addition to the above-mentioned mechanisms, other mechanisms such as the amplification of BRAF mutations [148] and/or alternative splicing of BRAF gene, are involved in the re-activation of the MAPK pathway, leading to the development of melanoma acquired resistance to BRAF inhibitors [149]. Here, BRAF is linked to melanoma.